157 related articles for article (PubMed ID: 34289564)
1. [The development and main achievements of clinical trials for anti-cancer investigational new drug in the past 60 years in China (1960-2020)].
Shi YK; Sun Y
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):696-706. PubMed ID: 34289564
[TBL] [Abstract][Full Text] [Related]
2. [The clinical trials of China innovative new anti-cancer drugs].
Shi YK; Sun Y
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):68-72. PubMed ID: 30678420
[TBL] [Abstract][Full Text] [Related]
3. [Progress on clinical trials of cancer drugs in China, 2020].
Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488
[No Abstract] [Full Text] [Related]
4. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
5. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
6. [Progress on clinical trials of cancer drugs in China, 2019].
Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
[No Abstract] [Full Text] [Related]
7. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
8. Reviewing concomitant medications for participants in oncology clinical trials.
McGahey KE; Weiss GJ
Am J Health Syst Pharm; 2017 Apr; 74(8):580-586. PubMed ID: 28389457
[TBL] [Abstract][Full Text] [Related]
9. [New therapeutic strategies in oncology].
Bohuon C
Ann Pharm Fr; 2010 Jul; 68(4):203-4. PubMed ID: 20637352
[No Abstract] [Full Text] [Related]
10. American society of clinical oncology - 45th annual meeting. Part 2.
Lakeram M; Kibble A
IDrugs; 2009 Jul; 12(7):404-8. PubMed ID: 19579155
[No Abstract] [Full Text] [Related]
11. American society of clinical oncology - 45th annual meeting. Part 1.
Gale S
IDrugs; 2009 Jul; 12(7):401-3. PubMed ID: 19579154
[No Abstract] [Full Text] [Related]
12. New scale assesses benefits of cancer medicines.
Bagcchi S
Lancet Oncol; 2015 Jul; 16(7):e316. PubMed ID: 26051234
[No Abstract] [Full Text] [Related]
13. [Drug development in paediatric oncology].
Benninger-Döring G; Boos J
Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
[TBL] [Abstract][Full Text] [Related]
14. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
[TBL] [Abstract][Full Text] [Related]
15. An appraisal of drug development timelines in the Era of precision oncology.
Jardim DL; Schwaederle M; Hong DS; Kurzrock R
Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
[TBL] [Abstract][Full Text] [Related]
16. American society of clinical oncology--41st annual meeting. Immunology.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):528-30. PubMed ID: 15973554
[No Abstract] [Full Text] [Related]
17. [Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021].
Huang HY; Wu DW; Zhu Q; Yu Y; Wang HX; Wang J; Ga M; Meng XY; Du JT; Miao SM; Zhao ZX; Wang X; Shang P; Guo MJ; Liu LH; Tang Y; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):276-281. PubMed ID: 35316878
[No Abstract] [Full Text] [Related]
18. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
19. The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.
Goldberg RM; Wei L; Fernandez S
Oncologist; 2017 Sep; 22(9):1015-1019. PubMed ID: 28620092
[TBL] [Abstract][Full Text] [Related]
20. Discontinued drugs in 2008: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
